T/NK/CAR-T Cell Therapy Product Thawing

• Use the cryopreserved T, NK, or CAR-T cell product, preservative-free normal saline when reproducing the published CAR-T locoregional thaw/wash method, or pre-warmed complete culture medium when post-thaw culture/recovery is part of an experimental workflow; DMSO-containing cryopreservation formulations are common in the cited literature, but this protocol does not prescribe a freezing formulation because the task is thawing rather than cryopreservation^[1][4][7][8].

• Use viability dyes or counting methods suitable for membrane-integrity viability, and use flow-cytometry reagents for CD3, CD4/CD8 or NK markers, CAR/transgene surface expression, CD107a degranulation, or intracellular effector molecules only when those endpoints are part of the study design^{[3][4][6][7][8]}.

• Use a temperature-controlled 37°C water bath or validated thawing system, sterile transfer vessels, centrifuge, biosafety cabinet or equivalent aseptic processing environment, cell counter or flow cytometer, and cytotoxicity-assay platform when functional release testing is required^{[2][4][6][7][8]}.

• Before thawing, define the post-thaw endpoint as direct infusion/use, thaw-and-wash, or thaw-rest-assay, because published CAR-T studies differ: many CAR-T studies thaw and use cells immediately, some experimental studies dilute or wash cells to reduce DMSO, and one CAR-T locoregional-delivery method validated a defined thaw/wash process with final syringe storage at 20-25°C for up to 3 h^[1][4][7][8].

• Prepare all diluent before removing the product from cryogenic storage; the Akel CAR-T thaw/wash method used 1 volume preservative-free normal saline for 5 min equilibration, then an additional 8 volumes preservative-free normal saline before washing and resuspension in 2.0 mL preservative-free normal saline^[4].

• Remove the cryopreserved cell container from cryogenic storage and thaw at 37°C; published T-cell and CAR-T studies report 37°C water-bath thawing, with some protocols thawing until a small ice crystal remains or until the suspension is just melted^[2][4][7][8].

• For a no-wash experimental workflow, transfer the thawed cell suspension promptly into the selected pre-warmed medium or assay buffer, mix gently, and proceed to cell counting, viability assessment, phenotype testing, functional assay, culture, or administration-related handling according to the study endpoint^[1][3][7][8].

• For the literature-supported CAR-T thaw/wash workflow, thaw at 37°C, add 1 product volume of preservative-free normal saline and equilibrate for 5 min, dilute with an additional 8 volumes preservative-free normal saline, remove DMSO by washing, resuspend the final product in 2.0 mL preservative-free normal saline, and hold in a syringe at 20-25°C only within the 3 h stability window validated in that study^[4].

• If centrifugation is used for experimental T-cell thaw recovery, one published T-cell/CAR-T recovery workflow diluted thawed cells into 9-10 mL medium and centrifuged for 5 min; reported centrifugal conditions varied by study and should therefore be copied only from the selected source protocol rather than generalized^[7][8].

• Measure immediate post-thaw viable cell recovery and viability, and when the product is CAR-T or NK, include identity/phenotype and function-oriented readouts such as CAR expression, CD4/CD8 composition, CD107a degranulation, cytokine production, or tumor-cell killing, because cryopreservation can preserve some functions while reducing others depending on cell type and assay^{[3][4][5][6][7][8]}.

• Use fresh or non-cryopreserved cells as the comparator when the experimental question is freeze-thaw impact, use thawed-not-washed cells as the comparator when the question is DMSO-removal impact, and include the functional target-cell assay controls needed for cytotoxicity interpretation^{[3][4][5][6][7][8]}.

Low viable recovery after thawing:

Possible cause
Freeze-thaw injury and delayed post-thaw cell death can reduce viable recovery, and T-cell studies show that cooling/thawing history and post-thaw culture time affect measured recovery.
Literature-supported solution:
Standardize the thawing temperature, thaw endpoint, dilution/wash timing, and recovery-assay time point, and report immediate and delayed post-thaw viability rather than relying on one time point^[2][7][9].

Reduced CAR-T functional readout after thawing:

Possible cause
Cryopreservation has been associated with altered apoptotic markers and reduced cytokine secretion in some CAR-T studies, although cytotoxic function may remain detectable.
Literature-supported solution:
Pair viability testing with CAR expression and functional assays such as cytotoxicity, cytokine release, or degranulation before interpreting thaw success^[3][7][8].

NK cells show reduced cytotoxicity despite acceptable viability:

Possible cause
NK-cell cryopreservation can impair migration and cytotoxicity in three-dimensional assays even when degranulation is retained.
Literature-supported solution:
Include a direct cytotoxicity assay, and where relevant a migration or 3D-function assay, rather than using viability alone as the release or comparison endpoint^[5][6].

DMSO removal is required for a specific experimental or delivery route:

Possible cause
DMSO remains in conventional cryopreserved products after thaw unless dilution/washing is performed.
Literature-supported solution:
Use the published CAR-T thaw/wash sequence of 37°C thaw, 1-volume saline equilibration for 5 min, 8-volume dilution, wash, 2.0 mL saline resuspension, and 20-25°C storage for up to 3 h only for a comparable CAR-T context^[4].